Haemonetics (NYSE:HAE) Price Target Raised to $144.00

Haemonetics (NYSE:HAE – Free Report) had its price target upped by Citizens Jmp from $115.00 to $144.00 in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage currently has a market outperform rating on the medical instruments supplier’s stock.

HAE has been the subject of several other reports. Wall Street Zen cut shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research note on Wednesday, November 4th. Barrington Research boosted their target price on Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Friday, November 6th. Citigroup upped their target price on Haemonetics from $123.00 to $149.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, BTIG Research increased their price target on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $130.50.

View Our Latest Research Report on Haemonetics

Haemonetics Price Performance

Shares of HAE opened at $122.78 on Monday. Haemonetics has a one year low of $51.00 and a one year high of $132.00. The stock’s fifty day moving average is $114.47 and its 200-day moving average is $82.19. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.83 and a current ratio of 2.84. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of 23.76, a price-to-earnings-growth ratio of 2.42 and a beta of 0.63.

Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. The business had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.27 earnings per share. Equities analysts anticipate that Haemonetics will post 5.32 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Farris Maryanne Maunsell sold 836 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total transaction of $101,147.64. Following the completion of the transaction, the chief accounting officer owned 5,828 shares in the company, valued at approximately $705,129.72. This trade represents a 12.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 2.07% of the company’s stock.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its position in Haemonetics by 30.8% in the third quarter. Goldman Sachs Group Inc. now owns 1,368,265 shares of the medical instruments supplier’s stock worth $144,078,000 after buying an additional 322,246 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Haemonetics by 1,191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after acquiring an additional 418,470 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Haemonetics during the 2nd quarter valued at $33,326,000. Finally, London Co. of Virginia boosted its stake in shares of Haemonetics by 33.9% during the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock worth $19,884,000 after acquiring an additional 89,242 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About Haemonetics

(Get Free Report)

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.

Featured Articles

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.